Deals channel feed – Endpoints News

Deals channel feed

Whale watching: What a decade of change at Big Pharma taught us about corporate phenotypes

7 years ago

T cell experts at Kiadis bag CytoSen's NK cell tech, plotting a dual cancer killing approach with tips from Carl June

7 years ago

Ahead of US gene therapy explosion, big contract drug manufacturer Catalent makes $1.2 billion bet on Paragon Bioservices

7 years ago

Bristol-Myers shareholders back the big Celgene buyout. What happens now?

7 years ago

Two Syncona-backed players join forces to take on retinal gene therapies

7 years ago

It’s a seller’s world in biotech M&A, and Novartis CEO Vas Narasimhan has his check book out and pen ready

7 years ago

Battered and out of options, Histogenics turns to eye drug developer Ocugen for reverse merger

7 years ago

To counter a lawsuit, Bristol-Myers outlines how the big Celgene buyout will shower $187M-plus on Morgan Stanley

7 years ago

As Spark shareholders balk, FTC holdup helps delay Roche's $4.3B buyout

7 years ago

The top 20 preclinical biotech deals ranked by cash upfront reveals 3 big players — and some major league stinkers

7 years ago

Novartis just signed a $1.6B buyout pact with a lead player in an emerging anti-inflammatory field

7 years ago

After gaining key support for Celgene buyout, Bristol-Myers CEO Caforio emerges as likely winner in looming shareholder vote

7 years ago

Celgene shares jump as Bristol-Myers gains key support from proxy adviser for looming buyout vote

7 years ago

AstraZeneca CEO Soriot bets up to $7B on a major league collaboration for a game-changing HER2 cancer drug

7 years ago

FTC demands more info from Bristol-Myers, Celgene on psoriasis drugs, signaling a potential hitch for $74B deal

7 years ago

Buyout vote looming, Celgene files for ozanimod OK (again), with a multibillion-dollar bet riding on every step

7 years ago

Thermo Fisher forges $1.7 billion deal to buy a contract player in the booming gene therapy field

7 years ago

Is a severely damaged Biogen looking to shed its ties to a controversial development partner?

7 years ago

Allergan chief Brent Saunders bows to activists, but Appaloosa blasts back that it's all too little, too late

7 years ago

J&J mops up $900M in waste, writing off the last big chunk of the $1.75B it spent to acquire Alios

7 years ago

Billionaire Bertarelli's Waypoint steers allergy drugmaker Stallergenes Greer private in $832M buyout deal

7 years ago

Bristol-Myers and Starboard Value spar over $74B Celgene buyout as shareholder vote looms

7 years ago

Partnering talks led to Biogen’s $800M Nightstar buyout as players clustered around the hot deal table for gene therapies

7 years ago

Bristol-Myers dodges a bullet as PTAB turns down inter partes review pitch for Celgene's cash cow

7 years ago

First page Previous page 103 104 105106107 108 109 Next page Last page